SCHEMBL26455754

SCHEMBL26455754

CCC/C=C\CCO[Si](CCCCN(C)CCCN(C)CCCC[Si](OCC/C=C\CCC)(OCC/C=C\CCC)OCC/C=C\CCC)(OCC/C=C\CCC)OCC/C=C\CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26455763 0.98
SCHEMBL26455751 0.86
SCHEMBL26455716 0.84 EPHX2 (0.38)
SCHEMBL26455766 0.84
SCHEMBL26455720 0.79 LPAR3 (0.41)
SCHEMBL24394423 0.79 LPAR2 (0.33)
SCHEMBL26455678 0.78
SCHEMBL26456508 0.78
SCHEMBL24394414 0.77 CNR1 (0.43)
SCHEMBL26456557 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577520-A1 PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF Renagade Therapeutics Management Inc. (US) 2025-07-02 EP claimed
EP-4262883-B1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2025-05-28 EP claimed
WO-2024044728-A1 PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2024-02-29 WO claimed
EP-4262883-A1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2023-10-25 EP claimed
WO-2022133344-A1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (US) 2022-06-23 WO claimed
EP-4617367-A2 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2025-09-17 EP disclosed
US-20240148663-A1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2024-05-09 US disclosed
EP-4262883-A1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2023-10-25 EP disclosed
US-20230139594-A1 CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS GENEVANT SCIENCES GMBH (CH) 2023-05-04 US disclosed
US-20230139594-A1 CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS GENEVANT SCIENCES GMBH (CH) 2023-05-04 US disclosed
WO-2022133344-A1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (US) 2022-06-23 WO disclosed